Cardiol Therapeutics Inc.

NASDAQ:CRDL

Drug Manufacturers - Specialty & Generic

Healthcare
$0.95 -0.47%

-$0.01 today

Market cap
$114.64M
Beta
0.80
P/E (TTM)
-4.5
EPS (TTM)
-$0.33
52W Low $0.88High $1.71

Volume 0.31M

Average 0.68M

CRDL EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Cardiol Therapeutics Inc.NASDAQ: CRDL

EBITDA · Q1 FY2026 · quarter ended Mar 2026

EBITDA remains negative

Q1 FY2026 EBITDA was -CA$10.82M, compared with -CA$8.26M a year earlier. Trailing-twelve-month EBITDA was -CA$36.27M.

Context

  • EBITDA grew in size in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 4 analysts of -CA$36.28M (-7.6%) for the fiscal year ending Dec 2026, a slowdown from the +7.7% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-CA$10.82M-50.6% QoQ
Last fiscal yearDec 2025
-CA$33.72M+7.7% YoY
LTMMar 2026
-CA$36.27M-16.2% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-30.9%——
1 year+7.7%-7.6%-15.3 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

CAD · from the income statement

Latest · FY2025
(33.72M) CAD
Year-over-year change
+7.7%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA vs competitors

How CRDL compares with its peers on the latest reported figures

  • Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -16.2% is the 6th highest of 10, against a peer median of -14.1%.
CRDL Competitors
EBITDA for CRDL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ASRTAssertio Holdings, Inc.LTM Mar 2026-$5.79M USD-288.4%-67.3%5.7%
MBOTMicrobot Medical Inc.LTM Mar 2026-$14.17M USD-22.2%—13493.3%
VANIVivani Medical, Inc.LTM Mar 2026-$26.64M USD-14.1%——
HYPRHyperfine, Inc.LTM Mar 2026-$33.15M USD+15.7%—216.2%
CRDLCardiol Therapeutics Inc.LTM Mar 2026-CA$36.27M CAD-16.2%——
IFRXInflaRx N.V.LTM Mar 2026-€42.36M EUR+1.6%—144435.8%
KLRSKalaris Therapeutics IncLTM Mar 2026-$44.08M USD+36.5%——
IMAImageneBio IncLTM Mar 2026-$51.64M USD-7.8%——
CNTBConnect Biopharma Holdings LimitedFY2025-$54.58M USD-270.2%—85279.7%
INCRInterCure Ltd.LTM Jun 2025-₪79.49M ILS-1677.7%—32.7%
Peer median (excluding CRDL) —-14.1%-67.3%6854.8%

Competitors are the stored peer set for CRDL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue62.27K0000
Cost of Revenue174.26K162.23K187.38K00
Gross Profit(112K)(162.23K)(187.38K)00
Gross Margin-179.9%————
Research & Development8.59M13.99M10.73M14.01M14.02M
Selling, General & Admin21.86M16.34M11.55M25.89M20.2M
Operating Expenses30.46M30.33M22.29M40.28M34.32M
Depreciation & Amortization174.26K162.23K187.38K162.11K101.98K
EBITDA(24.84M)(22.66M)(21.04M)(36.52M)(33.72M)
EBITDA Margin-39891.0%————
Operating Income(30.57M)(30.49M)(22.47M)(40.28M)(34.32M)
Operating Margin-49092.4%————
Interest Income106K1.24M2.04M1.19M726.4K
Interest Expense00000
Other Income / Expenses5.56M7.68M1.25M3.6M497.42K
Income Before Tax(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Pre-Tax Margin-40170.9%————
Income Tax Expense00000
Net Income(25.01M)(22.82M)(21.22M)(36.68M)(33.82M)
Net Margin-40170.9%————
EPS (Basic)(0.73)(0.49)(0.44)(0.51)(0.39)
EPS (Diluted)(0.73)(0.49)(0.44)(0.51)(0.39)
Weighted Avg Shares43.22M62.51M64.46M71.57M86.99M
Weighted Avg Shares (Diluted)43.22M62.51M64.46M71.57M86.99M

Cardiol Therapeutics Inc.

NASDAQ:CRDL

Intrinsic Alpha fair value

Locked

Current Price

$0.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.